Special Issue

Tuberculosis: *Mycobacterium tuberculosis*—Infection Control and Antibiotic Resistance

Message from the Guest Editors

Tuberculosis (TB) infection control represents a major subject of research in the scientific field, with TB being a serious condition that can be fatal if left untreated. Due to the use of antibiotics in the treatment of this infection and the long period of treatment required, the development of antibiotic-resistant bacteria in the infected patients may be reported. This Special Issue welcomes any type of papers that discuss infection and treatment of Mycobacterium tuberculosis. The treatment of tuberculosis is extremely challenging and requires the use of multiple drugs in a strict regimen, in order to obtain a successful cure. Taking this into consideration, we invite the contributors to submit manuscripts that describe the infection control, antibiotic treatment, ways of detection, transmission, prevention, diagnosis, risk factors and pathogenesis of this bacteria, new drugs and compounds for tuberculosis treatment, etc. Keywords: Mycobacterium tuberculosis: tuberculosis: antibiotic resistance: infection control; diagnosis; treatment

Guest Editors

Dr. Sandeep Upadhyay

National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC, USA

Prof. Dr. Chongguang Yang

School of Public Health (Shenzhen), Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou 510275, China

Deadline for manuscript submissions

closed (31 March 2024)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/185480

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

